Physician profile
Scott R Pulliam
NPI 1588625552
$2,465.88
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $665 · 2020: $204 · 2021: $160 · 2022: $837 · 2023: $600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $599.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $330.82 | 2019-2023 | Shingrix, Trelegy Ellipta, Bexsero |
| Lilly USA, LLC | $244.34 | 2019-2023 | Mounjaro |
| Abbvie INC. | $231.74 | 2020-2022 | |
| Novo Nordisk INC | $208.25 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.25 | 2019-2023 | Jardiance |
| Amgen INC. | $134.22 | 2019-2020 | |
| Amarin Pharma, INC. | $99.03 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $90.94 | 2022-2023 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $86.88 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $78.59 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $68.44 | 2019-2020 | |
| Abbott Laboratories | $63.95 | 2019-2023 | Freestyle Libre |
| Janssen Pharmaceuticals, INC | $60.14 | 2019-2023 | Xarelto |
| Teva Pharmaceuticals USA, INC. | $60.13 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $53.88 | 2022-2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $43.59 | 2020 | |
| Scilex Pharmaceuticals INC. | $38.80 | 2022 | |
| Exact Sciences Corporation | $36.10 | 2023 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $29.35 | 2022-2023 | |
| Kowa Pharmaceuticals America, INC. | $28.63 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.29 | 2019-2022 | |
| Pfizer INC. | $26.22 | 2019-2023 | |
| Insulet Corporation | $25.33 | 2022-2023 | Omnipod |
| Astellas Pharma US INC | $25.30 | 2019 | |
| Ironwood Pharmaceuticals, INC | $23.97 | 2019 | |
| Hikma Pharmaceuticals USA | $23.41 | 2022 | |
| Si-Bone, INC. | $19.87 | 2019 | |
| Dexcom, INC. | $19.33 | 2023 | Dexcom G6 Transmitter |
| Medtronic, INC. | $19.03 | 2022 | |
| Antares Pharma, INC. | $17.82 | 2022 | |
| Sanofi Pasteur INC. | $15.97 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.38 | 2019 | |
| Shire North American Group INC | $12.90 | 2019 | |
| Ibsa Pharma INC. | $12.90 | 2022 | |
| Merck Sharp & Dohme LLC | $11.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Pulliam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.